期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 61, 期 1, 页码 127-135出版社
SPRINGER
DOI: 10.1007/s00262-011-1173-5
关键词
Chimeric antigen receptor; T cell receptor; Adoptive T cell transfer; Immunotherapy; Gene transfer; CIMT 2011
资金
- University of Pennsylvania
- Commonwealth of Pennsylvania/Pennsylvania Department of Health [4100051725]
A central role for T cells in the control of cancer has been supported by both animal models and clinical observations. Accordingly, the development of potent anti-tumor T cell immunity has been a long-standing objective of immunotherapy. Emerging data from clinical trials that test T cell immune-modulatory agents and genetically engineered and re-targeted T cells have begun to realize the profound potential of T cell immunotherapy to target cancer. This review will focus on a description of recent conceptual and technological advances for the genetic engineering of T cells to enhance anti-tumor T cell immunity through the introduction of tumor-specific receptors, both Chimeric Antigen Receptors (CAR) and T cell receptors (TcR), as well as an overview of emerging data from ongoing clinical trials that highlight the potential of these approaches to effect dramatic and potent antitumor immunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据